×

Five Prime Therapeutics Announces Expansion of Respiratory Disease Research Collaboration and License Agreement With GSK

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), today announced an expansion of its respiratory disease research collaboration with GSK that was established in 2012 to identify first-in-class agents and new mechanisms for the treatment of refractory asthma and chronic obstructive pulmonary disease (COPD). The scope of the collaboration was increased in April 2014 to include two additional respiratory disease discovery programs for a six-month evaluation period, and GSK has now committed to continue these two discovery programs for an additional 18 months.

"GSK's decision to expand our collaboration speaks to the strength and versatility of our protein discovery platform to identify novel targets in a wide range of major respiratory diseases," said Aron Knickerbocker, senior vice president and chief business officer of Five Prime. "GSK is the leader in the discovery, development and commercialization of drugs for respiratory diseases and thus they are an ideal partner to have in this area of research."

"We are pleased to expand this highly collaborative research alliance with Five Prime to discover novel targets that have the potential to result in new medicines for the treatment of respiratory disease," said Edith Hessel, Vice President, Head of the Refractory Respiratory Inflammation Discovery Performance Unit at GSK. "We are hopeful these discoveries will lead to innovative new therapies that will benefit patients with uncontrolled respiratory disease."

Five Prime will receive $2 million in research funding for this expansion, $0.5 million of which Five Prime has already received. In the event that GSK licenses a target discovered by Five Prime in the collaboration, Five Prime would also be eligible to receive up to $193.8 million in potential option exercise fees and milestone payments, as well as tiered royalties on global net sales for each product resulting from a selected drug target.

About Five Prime

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in cancer immunotherapy, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.

Cautionary Note on Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Five Prime's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding Five Prime's potential receipt of research funding, option exercise fees, milestone payments and royalties. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Five Prime's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

CONTACT: Amy Kendall, Corporate Communications 415-365-5776 amy.kendall@fiveprime.com

Source:Five Prime Therapeutics, Inc.